Unknown

Dataset Information

0

Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date.


ABSTRACT: Nowadays the therapeutic landscape for advanced and metastatic urothelial carcinoma continues to evolve. The recent regulatory approval of enfortumab vedotin (EV) for the treatment of advanced urothelial cancer confirms the evolving role of antibody-drug conjugates. EV demonstrates a favorable profile in heavily pretreated patients with locally advanced or metastatic urothelial carcinoma. Early survival reports demonstrate a significant antitumor effectiveness along with a rather acceptable safety profile in a difficult-to-treat population.

SUBMITTER: Moussa M 

PROVIDER: S-EPMC7886109 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

altmetric image

Publications

Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date.

Moussa Mohamad M   Papatsoris Athanasios A   Abou Chakra Mohamed M   Dellis Athanasios A  

Drug design, development and therapy 20210211


Nowadays the therapeutic landscape for advanced and metastatic urothelial carcinoma continues to evolve. The recent regulatory approval of enfortumab vedotin (EV) for the treatment of advanced urothelial cancer confirms the evolving role of antibody-drug conjugates. EV demonstrates a favorable profile in heavily pretreated patients with locally advanced or metastatic urothelial carcinoma. Early survival reports demonstrate a significant antitumor effectiveness along with a rather acceptable safe  ...[more]

Similar Datasets

| S-EPMC8450892 | biostudies-literature
| S-EPMC7780177 | biostudies-literature
| S-EPMC8796084 | biostudies-literature
| S-EPMC8880907 | biostudies-literature
| S-EPMC7494003 | biostudies-literature
| S-EPMC7340645 | biostudies-literature
| S-EPMC6784850 | biostudies-literature
| S-EPMC11199536 | biostudies-literature
| S-EPMC7106979 | biostudies-literature
| S-EPMC8268971 | biostudies-literature